References
Evans PA, Norden CW, Rhoads S, Deobaldia J, Silber JL: In-vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy (1997) 41;1406
Bouilla HJ, Perri MB, Kauffman CA, Zervos MJ: Comparative in-vitro activity of quinupristin/dalfopristin against multidrug-resistantEnterococcus faecium. Diagnostic Microbiology and Infectious Disease (1996) 25:127–131
Zervos MJ: Vancomycin-resistantEnterococcus faecium infections in the ICU and quinupristin/dalfopristin. New Horizons (1996) 4:385–392
Rende-Fournier R, Leclercq R, Galimand M, Duval G, Courvalin P: Identification of the satA-gene encoding a streptogramin A acetyltransferase inEnterococcus faecium BM 4145. Antimicrobial Agents and Chemotherapy (1993) 37:2119–2125
Low DE: Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics. and initial clinical experience. Microbial Drue Resistance (1995) 1:223–234
Klare I, Heier H, Claus H, Böhme G, Marin S, Seltmann G, Hakenbeck R, Antanassova V, Witte W:Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microbial Drug Resistance (1995) 1:265–272
Woodford N, Palepou MF, Johnson AP, Chadwick PR, Bates J: Lancet (1997) 350:738
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Werner, G., Klare, I. & Witte, W. Association between quinupristin/dalfopristin resistance in glycopeptide-resistantEnterococcus faecium and the use of additives in animal feed. Eur. J. Clin. Microbiol. Infect. Dis. 17, 401–402 (1998). https://doi.org/10.1007/BF01691571
Issue Date:
DOI: https://doi.org/10.1007/BF01691571